标题
The role of the ALK receptor in cancer biology
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume 27, Issue suppl_3, Pages iii4-iii15
出版商
Oxford University Press (OUP)
发表日期
2017-02-04
DOI
10.1093/annonc/mdw301
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs
- (2016) Richard Bayliss et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib
- (2016) Sandeep Kodityal et al. LUNG CANCER
- Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
- (2016) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Zebrafish Leucocyte tyrosine kinase controls iridophore establishment, proliferation and survival
- (2016) Andrey Fadeev et al. Pigment Cell & Melanoma Research
- Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
- (2015) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
- (2015) R. Katayama et al. CLINICAL CANCER RESEARCH
- Signaling from Glia and Cholinergic Neurons Controls Nutrient-Dependent Production of an Insulin-like Peptide for Drosophila Body Growth
- (2015) Naoki Okamoto et al. DEVELOPMENTAL CELL
- Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non–small-cell Lung Cancer Exhibiting Resistance to Ceritinib
- (2015) Gouji Toyokawa et al. Journal of Thoracic Oncology
- Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
- (2015) Thomas F Eleveld et al. NATURE GENETICS
- Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism
- (2015) Barbara Witek et al. PLoS One
- Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand–receptor interactions
- (2015) Andrey V. Reshetnyak et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dynamics-Driven Allostery in Protein Kinases
- (2015) Alexandr P. Kornev et al. TRENDS IN BIOCHEMICAL SCIENCES
- Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors
- (2015) C. Voena et al. Cancer Immunology Research
- Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma
- (2015) Alex Cazes et al. Oncotarget
- Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma
- (2015) Nathan F. Moore et al. Oncotarget
- ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma
- (2014) Scott C. Bresler et al. CANCER CELL
- Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
- (2014) R. Katayama et al. CLINICAL CANCER RESEARCH
- Intragenic anaplastic lymphoma kinase (ALK) rearrangements: Translocations as a novel mechanism ofALKactivation in neuroblastoma tumors
- (2014) Susanne Fransson et al. GENES CHROMOSOMES & CANCER
- Emergence of New ALK Mutations at Relapse of Neuroblastoma
- (2014) Gudrun Schleiermacher et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
- (2014) Ted W. Johnson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib
- (2014) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- A Nice Problem to Have: When ALK Inhibitor Therapy Works Better Than Expected
- (2014) Robert C. Doebele Journal of Thoracic Oncology
- A Novel Fusion of TPR and ALK in Lung Adenocarcinoma
- (2014) Yoon-La Choi et al. Journal of Thoracic Oncology
- HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib
- (2014) Douglas D. Fang et al. Journal of Thoracic Oncology
- Identification of a Novel HIP1-ALK Fusion Variant in Non–Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib
- (2014) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- HIP1–ALK, a Novel Fusion Protein Identified in Lung Adenocarcinoma
- (2014) Mineui Hong et al. Journal of Thoracic Oncology
- The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non-Small Cell Lung Cancer Model Mice
- (2014) M. Mori et al. MOLECULAR CANCER THERAPEUTICS
- First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- (2014) Benjamin J. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Deorphanization of the human leukocyte tyrosine kinase (LTK) receptor by a signaling screen of the extracellular proteome
- (2014) H. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma
- (2014) G. Umapathy et al. Science Signaling
- The Neuroblastoma ALK(I1250T) Mutation Is a Kinase-Dead RTK In Vitro and In Vivo
- (2014) Christina Schönherr et al. Translational Oncology
- The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
- (2014) L. Friboulet et al. Cancer Discovery
- Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma
- (2013) S. R. P. McDonnell et al. BLOOD
- Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy inALK-Rearranged Non–Small Cell Lung Cancer and Predict Strategies to Overcome Resistance
- (2013) Zhao Chen et al. CLINICAL CANCER RESEARCH
- Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells
- (2013) Kamaraj Sattu et al. FEBS Journal
- NovelTRAF1-ALKfusion identified by deep RNA sequencing of anaplastic large cell lymphoma
- (2013) Andrew L. Feldman et al. GENES CHROMOSOMES & CANCER
- Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
- (2013) Justin F. Gainor et al. JOURNAL OF CLINICAL ONCOLOGY
- ALKin Lung Cancer: Past, Present, and Future
- (2013) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
- (2013) Thomas H. Marsilje et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of recurrentFGFR3fusion genes in lung cancer through kinome-centred RNA sequencing
- (2013) Ian J Majewski et al. JOURNAL OF PATHOLOGY
- Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
- (2013) Yael P Mossé et al. LANCET ONCOLOGY
- Anaplastic Lymphoma Kinase Is Required for Neurogenesis in the Developing Central Nervous System of Zebrafish
- (2013) Sheng Yao et al. PLoS One
- MicroRNA 96 Is a Post-Transcriptional Suppressor of Anaplastic Lymphoma Kinase Expression
- (2012) Deeksha Vishwamitra et al. AMERICAN JOURNAL OF PATHOLOGY
- The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma
- (2012) Teeara Berry et al. CANCER CELL
- Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis
- (2012) Shizhen Zhu et al. CANCER CELL
- Characterization of Rearrangements Involving the ALK Gene Reveals a Novel Truncated Form Associated with Tumor Aggressiveness in Neuroblastoma
- (2012) A. Cazes et al. CANCER RESEARCH
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma
- (2012) D. Chand et al. Disease Models & Mechanisms
- Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing
- (2012) Yeonjoo Jung et al. GENES CHROMOSOMES & CANCER
- Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma
- (2012) E L Carpenter et al. ONCOGENE
- Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma
- (2012) J Okubo et al. ONCOGENE
- Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells
- (2012) C Schönherr et al. ONCOGENE
- KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only
- (2012) Yuki Togashi et al. PLoS One
- Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684
- (2011) Christina Schönherr et al. BIOCHEMICAL JOURNAL
- MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression
- (2011) C. Desjobert et al. BLOOD
- miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma
- (2011) H. Matsuyama et al. BLOOD
- CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
- (2011) Hiroshi Sakamoto et al. CANCER CELL
- Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene
- (2011) A. K. Murugan et al. CANCER RESEARCH
- Anaplastic Lymphoma Kinase Spares Organ Growth during Nutrient Restriction in Drosophila
- (2011) Louise Y. Cheng et al. CELL
- ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
- (2011) J. M. Heuckmann et al. CLINICAL CANCER RESEARCH
- The Nucleophosmin-Anaplastic Lymphoma Kinase Oncogene Interacts, Activates, and Uses the Kinase PIKfyve to Increase Invasiveness
- (2011) Sophie Dupuis-Coronas et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas
- (2011) E Dejean et al. LEUKEMIA
- The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking
- (2011) P Mazot et al. ONCOGENE
- Anaplastic Lymphoma Kinase and Leukocyte Tyrosine Kinase: Functions and genetic interactions in learning, memory and adult neurogenesis
- (2011) Joseph B. Weiss et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- An Evolutionary Conserved Role for Anaplastic Lymphoma Kinase in Behavioral Responses to Ethanol
- (2011) Amy W. Lasek et al. PLoS One
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
- (2011) R. Katayama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Receptor Tyrosine Kinase Alk Controls Neurofibromin Functions in Drosophila Growth and Learning
- (2011) Jean Y. Gouzi et al. PLoS Genetics
- Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
- (2010) Christian C. Lee et al. BIOCHEMICAL JOURNAL
- Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors
- (2010) Roberto T. Bossi et al. BIOCHEMISTRY
- Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene
- (2010) Z. Chen et al. CANCER RESEARCH
- Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy
- (2010) T. Martinsson et al. CANCER RESEARCH
- Anterograde Jelly belly ligand to Alk receptor signaling at developing synapses is regulated by Mind the gap
- (2010) J. Rohrbough et al. DEVELOPMENT
- The biology and treatment of EML4-ALK non-small cell lung cancer
- (2010) Takaaki Sasaki et al. EUROPEAN JOURNAL OF CANCER
- The Tyrosine 343 Residue of Nucleophosmin (NPM)-Anaplastic Lymphoma Kinase (ALK) Is Important for Its Interaction with SHP1, a Cytoplasmic Tyrosine Phosphatase with Tumor Suppressor Functions
- (2010) Samar A. Hegazy et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Crizotinib — Latest Champion in the Cancer Wars?
- (2010) Bengt Hallberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
- (2010) James E. Butrynski et al. NEW ENGLAND JOURNAL OF MEDICINE
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA
- (2010) M Marzec et al. ONCOGENE
- Proteome-Wide Identification of Novel Binding Partners to the Oncogenic Fusion Gene Protein, NPM-ALK, using Tandem Affinity Purification and Mass Spectrometry
- (2009) Fang Wu et al. AMERICAN JOURNAL OF PATHOLOGY
- Defining the conserved internal architecture of a protein kinase
- (2009) Alexandr P. Kornev et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
- (2009) K. Takeuchi et al. CLINICAL CANCER RESEARCH
- High incidence of DNA mutations and gene amplifications of theALKgene in advanced sporadic neuroblastoma tumours
- (2008) Helena Carén et al. BIOCHEMICAL JOURNAL
- The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation
- (2008) Chiara Ambrogio et al. CANCER RESEARCH
- C. elegans Anaplastic Lymphoma Kinase Ortholog SCD-2 Controls Dauer Formation by Modulating TGF-β Signaling
- (2008) David J. Reiner et al. CURRENT BIOLOGY
- Identification of ALK as a major familial neuroblastoma predisposition gene
- (2008) Yaël P. Mossé et al. NATURE
- Activating mutations in ALK provide a therapeutic target in neuroblastoma
- (2008) Rani E. George et al. NATURE
- Oncogenic mutations of ALK kinase in neuroblastoma
- (2008) Yuyan Chen et al. NATURE
- Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
- (2008) Isabelle Janoueix-Lerosey et al. NATURE
- The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination
- (2008) Roberto Chiarle et al. NATURE MEDICINE
- A mouse model for EML4-ALK-positive lung cancer
- (2008) M. Soda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Leukocyte Tyrosine Kinase Functions in Pigment Cell Development
- (2008) Susana S. Lopes et al. PLoS Genetics
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started